Craneware PLC (CRW.L) — Investment Research Note

Executive summary

Craneware is a vertical SaaS provider of financial, revenue-cycle and 340B pharmacy software to US hospitals (≈40% of US hospitals are customers), with a proprietary dataset of >200m patient encounters powering its Trisus cloud platform. Across the period covered, the business has executed a transformational Sentry acquisition (FY22), rebuilt operating leverage post-integration (FY24 Adj. EBITDA margin 31% → FY25 32% → H1 FY26 32%) and is now back to delivering double-digit Adjusted EBITDA and EPS growth on mid-single-digit revenue growth, with a new $25m buyback announced 2026-03 H1 FY26. The single most important point for valuation today is that the Board unanimously rejected an unsolicited approach at £26.50/share in mid-2025 — a strong private-market floor versus today's £529m market cap (~£14.89/share) 2025-09 FY25.

Fair value estimate

• Range: 1,700p – 2,100p per share (implied market cap £604m – £746m), mid ≈ £675m.
• Methodology: blended forward EPS multiple + EV/EBITDA cross-check, anchored by the rejected 2,650p approach. H1 FY26 adj. diluted EPS was 57.6¢; annualising and applying typical seasonality gives FY26E adj. EPS of ~$1.25–1.30 (~92–96p at $1.35/£). 18–22× FY26E adj. EPS = 1,656–2,112p. EV/EBITDA cross-check: FY26E Adj. EBITDA ~$70m → EV ~$770–910m at 11–13×, equity ~£600–710m after net cash of ~$48m 2026-03 H1 FY26.
• Key assumptions: 6–8% revenue growth, EBITDA margin held >30%, 340B Shelter and AI products convert to ARR, no further M&A.
• Versus current £529m mcap: mid-case upside ≈ +28%; range +14% to +41%.

Sector context

• ICB sector confirmed: Health Care, specifically healthcare IT / vertical SaaS. The reporting unit is functionally a US software business listed in London.
• Quality vs peers: above-average — 87% gross margin, 32% Adj. EBITDA margin, >90% gross retention, 103–107% NRR, net cash, founder-led. Closer in profile to high-quality vertical SaaS than to a typical UK healthcare name.
• Listed peers: Veeva Systems (NYSE:VEEV), HealthStream (NASDAQ:HSTM), Definitive Healthcare (NASDAQ:DH); Phreesia (NYSE:PHR) for hospital workflow. Sentry's prior owner ABRY-style private comps trade at higher multiples than CRW currently.

Investment thesis (3 bullets)

• Genuine AI leverage on proprietary data + Microsoft alliance, with revenue conversion already visible. Trisus Assist (co-built with Microsoft, launched March 2025) is now used by 200+ customers; H2 FY26 brings AI-enabled Labor Productivity and Reimbursement Intelligence into mission-critical workflows priced on top of existing seats. 200m+ patient encounters create a hard-to-replicate AI training corpus, and Sales to "new" customers jumped from 2% to 12% of new sales H1-on-H1, attributed to AI/competitive take-outs 2026-03 H1 FY26; 2025-09 FY25.
• Re-acceleration with operating leverage intact. Three-year history of EBITDA margin rebuild post-Sentry (28.75% H1 FY22 → 32% H1 FY26) on the same fixed cost base. Each incremental ARR dollar carries near-software-grade gross margin; FY25 delivered 9% revenue growth → 12% EBITDA growth → 22.5% adj. EPS growth as financial leverage worked in reverse via debt paydown 2025-09 FY25; 2026-03 H1 FY26.
• Asymmetric valuation with a hard floor. The Board rejected an unsolicited 2,650p approach in H2 FY25; the current 1,489p is ~44% below that mark, despite materially stronger ARR, balance sheet (net cash $48m vs net debt at the time of the bid) and AI optionality. Board response was endorsed by shareholders 2025-09 FY25. New $25m buyback + raised dividend reinforce the floor 2026-03 H1 FY26.

Key risks (3 bullets)

• 340B regulatory risk. The HRSA Rebate Pilot was announced then stayed by a US District Court; Craneware deferred ARR activation on the rebate module. Future federal/state 340B reform could either expand the opportunity (current view) or compress it materially. Rebate, Maximum Fair Price and ongoing political pressure on 340B are all live 2026-03 H1 FY26; 2025-11 AGM.
• Professional services and ARR growth still trail revenue growth. ARR grew only 4% to $184.2m in H1 FY26 while revenue grew 6% — partly because Platform Revenues (non-recurring) of $14.6m are not yet in ARR. If those don't convert to recurring, the "double-digit growth" narrative weakens 2026-03 H1 FY26.
• AI partner dependency. Trisus Assist and the agentic AI roadmap are co-developed with Microsoft on Azure; the MACC commitment and dependency on Microsoft's enterprise sales motion mean a deterioration in that relationship would meaningfully slow AI monetisation 2026-03 H1 FY26; 2024-09 FY24.

Operating leverage

Classic specialist SaaS with high fixed R&D and a largely fixed central cost base. FY25: Revenue $205.7m, COGS $26.4m (87% GM), R&D $57.3m total of which $14.9m capitalised — so ~$42m fixed annual R&D expense funded out of gross profit. Sales/admin/client servicing combined was $114m, growing 10% on 9% revenue growth (i.e. essentially fixed-cost discipline at the corporate level), driving the EBITDA margin from 31% to 32% on 9% top-line growth 2025-09 FY25. H1 FY26 repeated the pattern: 6% revenue growth → 10% Adj. EBITDA growth → 16% adj. EPS growth as deleveraging compounded the operating gearing 2026-03 H1 FY26. A 10–20% revenue beat from current expectations would, on this cost base, plausibly drop ~80–90% to incremental EBITDA — meaning Adj. EBITDA could move from ~$70m to ~$85–95m, a ~30–40% incremental EBITDA rise on a 15% revenue surprise. The constraint on a multiple of profit (rather than 1.3–1.5x) is that they will reinvest part of any upside into AI R&D, as explicitly signalled.

Value-trap signals

None identified. Revenue is accelerating, ARR is growing, customer retention >90%, no dividend cuts (dividend raised), management track record solid, no related-party concerns disclosed, no going-concern flags, low customer concentration (top 10 = 30% of revenue), regulatory risk acknowledged and actively managed. The one trapdoor to watch — 340B reform — is more "asymmetric event risk" than structural decline.

Earnings vs. expectations

The pattern across the period is beats and in-line, no misses. FY25 trading update (July 2025) flagged results "ahead of consensus market expectations" (adj. EBITDA over $65m, revenue $205.7m, NRR 107%) 2025-07 FY25 trading update. H1 FY26 trading update (Jan 2026) and full H1 results (Mar 2026) both confirmed "in line with market expectations" with double-digit EBITDA and EPS growth. FY24 was the only year with a softer revenue print versus initial market hopes (professional services lagging post-COVID), but EBITDA still grew. Across 5 years there have been no profit warnings or sequential guidance cuts — consistent with the SaaS revenue recognition model that gives management high visibility before the year starts.

Conviction

4 — high.

• Anchoring factors: (1) clean, well-disclosed SaaS metrics (ARR, NRR, gross retention, cash conversion all reported consistently); (2) multiple valuation approaches (forward P/E, EV/EBITDA, rejected-bid anchor) converge on a similar 1,700–2,100p range; (3) durable business model with 25+ years and a recently raised dividend + new buyback.
• Limiting factors: (1) 340B regulatory outcome could swing fair value meaningfully in either direction within 12 months; (2) the AI-monetisation thesis depends on FY27 ARR conversion that is not yet evidenced in numbers.

Driver scoring

• ai_beneficiary 60 — Vertical SaaS with proprietary data (200m patient encounters), embedded AI agents (Trisus Assist) and a deep Microsoft partnership. Not a pick-and-shovel name but a credible AI-augmented SaaS where incremental seat value grows with agents. Not 70+ because AI revenue is still nascent.
• operating_leverage 75 — Software economics (87% GM, 32% EBITDA margin), high fixed R&D, deleveraging tailwind. Demonstrated 10% EBITDA growth on 6% revenue growth in latest period.
• earnings_surprise_trend 65 — Consistent beats/in-line across 5 years; FY25 explicitly ahead of consensus; no profit warnings.
• cyclicality 18 — US hospital subscription software; defensive, multi-year contracts, no economic cycle exposure of note.
• moat 75 — 25+ years, 40% of US hospitals, switching costs, regulatory data complexity, 15× Best in KLAS, Microsoft partner status.
• leverage 12 — Net cash position (cash $71.2m vs bank debt $23.4m at H1 FY26), $176m undrawn facilities. Fortress balance sheet.
• earnings_quality 70 — Strong cash conversion (94% FY25), but ~$21m/yr of acquired-intangible amortisation creates a large statutory-vs-adjusted gap; some judgement around capitalised R&D ($14.9m FY25).
• management_quality 75 — Founder-CEO Keith Neilson holds 9.05%, recently paid £326k to retain shares from option exercise (alignment); rejected £26.50 bid; well-executed Sentry integration; clear capital allocation (debt down, dividend up, buyback now).
• growth_momentum 62 — Revenue +6–9%, ARR +4–7%, Adj. EBITDA double-digit growth, sales mix improving with new-logo win-rate rising. Not yet accelerating to double-digit revenue but trajectory is upward.

overall_score: 665

Strong on operating leverage, balance sheet, moat and valuation discipline; the £529m market cap is meaningfully below both fundamentally-derived fair value (£600–740m) and a recent rejected takeover (£935m), which limits downside. The throttle on a higher score is the AI angle: it is real and growing but not yet a dominant value driver (vertical SaaS with AI agents, not infrastructure). Fits the strategy as a "right idea, available at a fair price" name.